Sergio Buccheri1, Giovanna Sarno1, Ole Fröbert2, Thorarinn Gudnason3,4, Bo Lagerqvist1, Daniel Lindholm1, Michael Maeng5, Göran Olivecrona6, Stefan James1. 1. Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Sweden (S.B., G.S., B.L., D.L., S.J.). 2. Department of Cardiology, Örebro University Hospital, Sweden (O.F.). 3. Landspitali University Hospital, Reykjavik, Iceland (T.G.). 4. Department of Cardiology and Cardiovascular Research Center, University of Iceland, Reykjavik (T.G.). 5. Department of Cardiology, Aarhus University Hospital, Denmark (M.M.). 6. Department of Cardiology, Clinical Sciences, Lund University Hospital, Sweden (G.O.).
Abstract
BACKGROUND: Registry-based randomized clinical trials have emerged as useful tools to provide evidence on the comparative efficacy and safety of different therapeutic strategies. However, it remains unknown whether the results of registry-based randomized clinical trials have a sizable impact on daily clinical practice. We sought, therefore, to describe the temporal trends in thrombus aspiration (TA) use in Sweden before, during, and after dissemination of the TASTE trial (Thrombus Aspiration in ST-Elevation Myocardial Infarction in Scandinavia) results. METHODS AND RESULTS:From January 1, 2006, to December 31, 2017, we included all consecutive patients with ST-segment-elevation myocardial infarction undergoing percutaneous revascularization in Sweden. All patients were registered in the Swedish Coronary Angiography and Angioplasty Registry. A total of 55 809 ST-segment-elevation myocardial infarction patients were included. TA use in Sweden substantially decreased after dissemination of TASTE results (from 39.8% to 11.8% during and after TASTE, respectively). Substantial variability in TA use across treating centers was observed before TASTE (TA use ranging from 0% to 70%), but after TASTE both the interhospital variability and the frequency of TA use were markedly reduced. A constant shift in medical practice was seen about 4 months after dissemination of the TASTE trial results. Time trends for all-cause mortality and definite stent thrombosis at 30 days were not associated with variations in TA use ( P values >0.05 using the Granger test). CONCLUSIONS: In Sweden, the results of the TASTE trial were impactful in daily clinical practice and led to a relevant decrease in TA use in ST-segment-elevation myocardial infarction patients undergoing percutaneous revascularization.
RCT Entities:
BACKGROUND: Registry-based randomized clinical trials have emerged as useful tools to provide evidence on the comparative efficacy and safety of different therapeutic strategies. However, it remains unknown whether the results of registry-based randomized clinical trials have a sizable impact on daily clinical practice. We sought, therefore, to describe the temporal trends in thrombus aspiration (TA) use in Sweden before, during, and after dissemination of the TASTE trial (Thrombus Aspiration in ST-Elevation Myocardial Infarction in Scandinavia) results. METHODS AND RESULTS: From January 1, 2006, to December 31, 2017, we included all consecutive patients with ST-segment-elevation myocardial infarction undergoing percutaneous revascularization in Sweden. All patients were registered in the Swedish Coronary Angiography and Angioplasty Registry. A total of 55 809 ST-segment-elevation myocardial infarctionpatients were included. TA use in Sweden substantially decreased after dissemination of TASTE results (from 39.8% to 11.8% during and after TASTE, respectively). Substantial variability in TA use across treating centers was observed before TASTE (TA use ranging from 0% to 70%), but after TASTE both the interhospital variability and the frequency of TA use were markedly reduced. A constant shift in medical practice was seen about 4 months after dissemination of the TASTE trial results. Time trends for all-cause mortality and definite stent thrombosis at 30 days were not associated with variations in TA use ( P values >0.05 using the Granger test). CONCLUSIONS: In Sweden, the results of the TASTE trial were impactful in daily clinical practice and led to a relevant decrease in TA use in ST-segment-elevation myocardial infarctionpatients undergoing percutaneous revascularization.
Authors: A G Fraser; R G H H Nelissen; P Kjærsgaard-Andersen; P Szymański; T Melvin; P Piscoi Journal: Eur Heart J Qual Care Clin Outcomes Date: 2022-05-05
Authors: Robin Hofmann; Tamrat Befekadu Abebe; Johan Herlitz; Stefan K James; David Erlinge; Joakim Alfredsson; Tomas Jernberg; Thomas Kellerth; Annica Ravn-Fischer; Bertil Lindahl; Sophie Langenskiöld Journal: Front Public Health Date: 2022-01-12
Authors: Anthony A Matthews; Issa J Dahabreh; Ole Fröbert; Bertil Lindahl; Stefan James; Maria Feychting; Tomas Jernberg; Anita Berglund; Miguel A Hernán Journal: Am J Epidemiol Date: 2022-08-22 Impact factor: 5.363